Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

27.74 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jun 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,371
Open 27.74
Bid (Size) 27.70 (10)
Ask (Size) 27.75 (2)
Prev. Close 27.74
Today's Range 27.74 - 27.74
52wk Range 25.20 - 39.24
Shares Outstanding 5,606,688,356
Dividend Yield 5.91%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy
The agency signed off on Elevidys for a broad population of children with the muscle-wasting disease. 
Via Investor's Business Daily
Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer
GSK, supported by major industry groups, seeks to stop 70,000 Zantac lawsuits in Delaware, arguing a recent court ruling threatens the state's business-friendly reputation and judicial consistency. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal

Performance

YTD
-6.69%
-6.69%
1 Month
-2.87%
-2.87%
3 Month
+0.29%
+0.29%
6 Month
-2.01%
-2.01%
1 Year
-28.69%
-28.69%

More News

Read More
Skip Meme Mania: 3 Undervalued Blue-Chip Stocks for Steady Returns
Via InvestorPlace
Supreme Court Upholds 2017 Tax On Foreign Profits For US Businesses
Via Benzinga
3 Underrated Dividend Stock Machines to Turbocharge Your Income
Via InvestorPlace
How Is The Market Feeling About Pfizer?
Via Benzinga
Is It Too Late to Buy Pfizer Stock?
Via The Motley Fool
7 High-Value Blue-Chip Stocks to Boost Your Wealth by 2027
Via InvestorPlace
Palantir, Oracle, Pfizer Chiefs Lobby US Lawmakers For Israel's Support Amid Hamas Attack, Hostage Crisis
Via Benzinga
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
Via Benzinga
Exposures COVID-19
Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb
Via The Motley Fool
Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
FDA Approves Merck's Pneumococcal Vaccine As First Shot Designed For Adults
Via Benzinga
Exposures Product Safety
Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?
Via Benzinga
Exposures Product Safety
Pfizer's COVID-19 Vaccine Safety Claims Under Lens, Faces Lawsuit From Kansas For Alleged Misleading Claims
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
Via MarketBeat
Exposures COVID-19
Precision Medicine M&A is Transforming the Future of the Biotech Industry
Via AB Newswire
3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade
Via The Motley Fool
Topics Stocks
Exposures US Equities
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
Via Investor's Business Daily
3 Stocks to Sell as Ozempic Surges in Popularity
Via InvestorPlace
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
From Pfizer Inc.
Via Business Wire
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Via Investor's Business Daily
Exposures Product Safety
What's Going On With Pfizer On Thursday? Pharma Giant's Shares Tick Lower
Via Benzinga
Exposures COVID-19
3 Ultra-High-Yield Dividend Stocks Billionaires Are Sinking Their Teeth Into
Via The Motley Fool
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy
From Pfizer Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Diversified Communications
© 2023 Diversified Communications. All rights reserved.